

5

Disruptive Innovation in Population Health: Pharma's Role in Improving Health Outcomes

Kalahn Taylor-Clark, PhD, MPH Sanofi






"THE VIEWS EXPRESSED IN THE PRESENTATION ARE THOSE OF THE PRESENTER AND DO NOT NECESSARILY REFLECT THOSE OF SANOFI US".

Roadmap

- Background: Goals and Current State of Health and Healthcare in the U.S.
- Changes in the U.S. Health System: Implications for Pharma Volume → Value Process → Outcomes
- Role of Pharma in Accelerating Improvements in Population Health


A Changing Demographic

Prevalence of two or more of nine selected chronic conditions among adults aged 45 and over, by race/ethnicity: United States, 1999–2000 and 2009–2010



Spending on Health in the U.S.

U.S. Health care spending breakdown, 2010



Source: Center for Medicare and Medicald Services

Key challenges and opportunities for Population Health Management

- Data integration and insight
- Value-based purchasing and reimbursement
- Patient engagement: extending access through community health
- Care coordination and management through Integrated Delivery Networks (IDNs) and Patient-Centered Medical Homes (PCMHs)
- Organizational change and physician education/evolution to support the above
- Managing the escalating cost of Specialty Pharmaceuticals

Patient Engagement is a Strategic Imperative in a Shifting Health Care Delivery Environment


For Key Stakeholders		
	PATIENTS	Need for more rapid and efficient drug development; Focus on self-management
6	HEALTH CARE PROVIDERS	Volume → Value
\$	PAYERS	 ✓ Moving from "individual payers" to "organized payer groups" ✓ Shift to value-based purchasing (including measures of patient outcomes and experience)
	REGULATORS	Increased inclusion of Patient Reported Outcomes
	EMPLOYEES	Increased sense of purpose and pride
2	SHAREHOLDERS	Recognized as a company that anticipates and meets patients' needs; sustainable business model focused on outcomes

Examples: Patient Engagement-Extending Access Through Community Health

New sites of care: home, retail, community social networks

- Examples of efforts to encourage patient engagement and improve adherence and population health outcomes:
 - Offer discounts to patients who complete entire course of treatment and offer "first fill" support programs
 - Ensure patient views are reflected in value-based assessments of innovative therapies
 - Encourage development of clinical decision supports for "at-risk" populations and patients and providers
 - Support patient-relevant outcomes data collection and analysis
 - Go BEYOND THE PILL...Develop Accountable Medical Villages, in which delivery system actors (e.g. provider groups, hospitals, pharmaceuticals, and community organizations) partner to provide maximum access to innovative therapies and high quality care

SO WHAT'S NEW? Moving to a "RTP" (Return to the Patient)



Thank you.

Kalahn.taylor-clark@sanofi.com